Business Wire

GA-PINDROP

4.5.2022 15:02:13 CEST | Business Wire | Press release

Share
Pindrop Partners with Google Cloud to Transform Contact Center Security and Enhance the Customer Experience with AI

Pindrop , a global leader in voice technology, today announced a new partnership with Google Cloud that will enable it to build and offer new authentication solutions to enhance call center experiences for customers on Google Cloud’s platform. Pindrop will also make its suite of fraud detection and voice security solutions available on Google Cloud Marketplace, as it is now part of the Google Cloud Partner Advantage Program as an Independent Software Vendor (ISV) partner.

Through this partnership, Pindrop plans to offer its call center security and anti-fraud protection solutions with Google Cloud’s Contact Center AI to deliver voice authentication and security solutions that create better experiences for the customer, add security to the call center, and increase flexibility with modern infrastructure. Using Google Cloud’s secure, trusted, and global infrastructure, Pindrop will also be able to deploy new voice security solutions that will give customers the ability to easily automate device-based interactions. Additionally, as a Google Cloud Partner, the two companies will execute a joint go-to-market strategy via Google Cloud Marketplace to augment Pindrop’s products with Google Cloud capabilities in AI, ML, analytics, and more.

“This is another historic moment for Pindrop, and we are thrilled about the partnership with Google Cloud. Together with Google Cloud, we are uniquely positioned to offer customers something genuinely innovative and drive toward our shared vision in the modern contact center world,” said Vijay Balasubramaniyan, CEO and co-founder at Pindrop. “By partnering with Google Cloud, we are truly on the path to delivering on our mission of making technology more human and helping our clients open new worlds by unlocking the power of the human voice.”

“Securing voice-driven call center and support services is a critical requirement for the enterprise technology stack today,” said Nirav Sheth, Director of Partnerships, Google Cloud. “We're thrilled to have innovative technology businesses like Pindrop building on Google Cloud. With Pindrop’s solutions available on Google Cloud Marketplace, organizations will be able to easily deploy Pindrop in their cloud environment and provide AI-enhanced experiences that prioritize secure, satisfactory customer interactions.”

Pindrop helps organizations across financial services, insurance, retail, healthcare, and telecommunications secure voice interactions with passive voice authentication and streamlined automatic number identification (ANI) verification solutions. By deploying Pindrop solutions in their multicloud environments, customers are empowered with the technologies needed to reduce costs associated to fraud loss and increase positive customer care experiences in the call center. A recent Pindrop commissioned Forrester TEI study found that Pindrop customers, who participated in the study, experienced a 10% increase in operational gains for call centers, 15% reduction in fraud incidents and losses, and improved call containment in the IVR by 2% leading to a better experience for customers and employees.

For more information about Pindrop, please visit www.pindrop.com .

About Pindrop

In an increasingly digital world, Pindrop lets people use their voice to seamlessly connect to, enter and unlock new experiences while helping safeguard their privacy. Using its patented voice authentication technology, Pindrop is leading the way to the future of voice by establishing the standard for identity, security, and intelligence for voice interactions. Working with some of the world’s biggest banks, insurers, and retailers, Pindrop enables customers to quickly, conveniently, and securely connect to the information and resources they need. Its voice authentication technology analyzes unique features within the human voice and surrounding audio that enables its customers to prevent fraud and deliver exceptional customer experiences in call centers, when obtaining information from smart devices, and even when activating cars. A privately held company, Pindrop is venture-backed by Andreessen Horowitz, Citi Ventures, Felicis Ventures, CapitalG, GV, IVP, and Vitruvian Partners. Visit pindrop.com for more information.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye